Acute injury protocol: Weeks 12: 500mcg each peptide twice daily, localized + systemic Weeks 34: 500mcg each peptide once daily, systemic Weeks 56: 250mcg each peptide once daily, systemic Total duration: 6 weeks Chronic condition protocol: Weeks 14: 500mcg each peptide once daily Weeks 58: 250500mcg each peptide once daily (based on response) Weeks 912: 250mcg each peptide once daily or every other day Total duration: 12 weeks Post-surgical protocol: Days 17: 500mcg each peptide twice daily Weeks 24: 500mcg each peptide once daily Weeks 56: 250mcg each peptide once daily Total duration: 6 weeks Monitoring and Adjustments Protocols should track the following
The references below summarise the mechanism-of-action and translational rat-model evidence base most relevant to the orthopedic and connective-tissue repair claims discussed in this article
Alkali-Burn Wound Healing, VEGF-A & ERK1/2 (PMC / Dove Press, 2015) A controlled study published in PMC and Dove Press investigated BPC-157s effects on alkali-burn wound healing in vivo and on HUVEC (human umbilical vein endothelial cell) behaviour in vitro
Start with a moderate, consistent dose (e.g
Freezing and thawing can cause the peptide to aggregate and lose potency
Semaglutide sodium is the salt form, which has a slightly higher molecular weight than semaglutide base